Sweet Tidings as vTv Therapeutics announces additional positive data from its Type 1 diabetes clinical trial
vTv Therapeutics (NASDAQ: VTVT), a clinical stage biotechnology company, presented additional positive data from a phase 2 Simplici-T1 study in patients with type 1 diabetes (T1D) at the Annual Meeting of the European Association for the Study of Diabetes in Barcelona. The clinical trial is...
